Clinical Trial Update: A Study of NGM282 in Patients With Primary Sclerosing Cholangitis [Phase 2]

View source ↗

Summary

A Phase 2 study of NGM282 for primary sclerosing cholangitis has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sclerosing Cholangitis

Drugs mentioned

• NGM282 (Aldafermin) (Aldafermin)

Snippet

Sponsor: NGM Biopharmaceuticals, Inc | Conditions: Primary Sclerosing Cholangitis | Phase 2 | Status: COMPLETED | Results posted: 2025-06-17